Image alt tag

Error!

There was a problem contacting the server. Please try after sometime.

Sorry, we are unable to process your request.

Error!

We're sorry, but the Insights and Intelligence Tool is temporarily unavailable

If this problem persists, or if you need immediate assistance, please contact Customer Service at 1-888-522-2388.

Error!

We're sorry, but the Literature Center checkout function is temporarily unavailable.

If this problem persists, or if you need immediate assistance, please contact Customer Service at 1-888-522-2388.

Tracked Funds

You have 0 funds on your mutual fund watch list.

Begin by selecting funds to create a personalized watch list.

(as of 12/05/2015)

Pending Orders

You have 0 items in your cart.

Subscribe and order forms, fact sheets, presentations, and other documents that can help advisers grow their business.

Reset Your Password

Financial Professionals*

Your password must be a minimum of characters.

Confirmation Message

Your LordAbbett.com password was successully updated. This page will be refreshed after 3 seconds.

OK

 

Developing Growth Fund

Summary

Summary

What is the Developing Growth Fund?

The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of small U.S. companies.

Fund Basicsas of 10/31/2019

Total Net Assets
$1.80 B
Inception Date
06/30/2015
Dividend Frequency
Annually
Fund Expense Ratio
0.69%
Number of Holdings
92

Fund Expense Ratio :

0.69%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge 25.78% 11.25% 21.14% 9.33% 15.69% -
Lipper Category Avg. Small-Cap Growth Funds 20.03% 7.83% 14.76% 8.98% 13.31% -
Russell 2000® Growth Index 18.62% 6.40% 13.22% 8.38% 13.38% -

Fund Expense Ratio :

0.69%

Fund Expense Ratio :

0.69%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge 23.10% -6.33% 17.38% 10.13% 14.58% -
Lipper Category Avg. Small-Cap Growth Funds 17.83% -6.59% 12.06% 9.68% 12.44% -
Russell 2000® Growth Index 15.34% -9.63% 9.79% 9.08% 12.25% -

Fund Expense Ratio :

0.69%

TEN LARGEST HOLDINGS as of 10/31/2019View Portfolio

Holding Assets
Generac Holdings, Inc. 3.1%
Inphi Corp. 2.3%
YETI Holdings Inc 2.2%
Repligen Corp. 2.1%
Inspire Medical Systems Inc 1.9%
Roku Inc 1.9%
RealReal Inc/The 1.8%
Bright Horizons Family Solutions, Inc. 1.8%
Tandem Diabetes Care, Inc. 1.8%
Coherus Biosciences, Inc. 1.7%

Investment Team

F. Thomas O'Halloran
F. Thomas O'Halloran, J.D., CFA

Partner & Portfolio Manager

32 Years of Industry Experience

Matthew DeCicco
Matthew R. DeCicco, CFA

Managing Director & Portfolio Manager

20 Years of Industry Experience

Vernon Bice
Vernon Bice, CMT

Portfolio Manager

18 Years of Industry Experience

Supported By 6 Investment Professionals with 18 Years Avg. Industry Experience

Your Representative

To contact your representative, enter your zip code and select your channel below.

Performance

Performance

Fund Expense Ratio :

0.69%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge 25.78% 11.25% 21.14% 9.33% 15.69% -
Lipper Category Avg. Small-Cap Growth Funds 20.03% 7.83% 14.76% 8.98% 13.31% -
Russell 2000® Growth Index 18.62% 6.40% 13.22% 8.38% 13.38% -

Fund Expense Ratio :

0.69%

Fund Expense Ratio :

0.69%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge 23.10% -6.33% 17.38% 10.13% 14.58% -
Lipper Category Avg. Small-Cap Growth Funds 17.83% -6.59% 12.06% 9.68% 12.44% -
Russell 2000® Growth Index 15.34% -9.63% 9.79% 9.08% 12.25% -

Fund Expense Ratio :

0.69%

Year Fund Returns Russell 2000® Growth Index
2018 5.32% -9.31%
2017 30.27% 22.17%
2016 -2.48% 11.32%
2015 -8.64% -1.38%
2014 3.56% 5.60%
2013 57.77% 43.30%
2012 10.73% 14.59%
2011 -1.30% -2.91%
2010 37.01% 29.09%
2009 47.54% 34.47%
2008 -47.31% -
2007 36.29% -
2006 12.86% -
2005 12.31% -
2004 6.39% -
Year Q1 Q2 Q3 Q4 Yearly Returns
2019 27.10% 9.18% -11.29% - 27.87%
2018 7.20% 15.07% 12.22% -23.91% 5.32%
2017 8.45% 4.10% 7.14% 7.71% 30.27%
2016 -10.24% 2.28% 10.94% -4.25% -2.48%
2015 7.18% 2.69% -15.63% -1.62% -8.64%
2014 1.76% 0.24% -5.71% 7.66% 3.56%
2013 13.60% 10.13% 18.88% 6.09% 57.77%
2012 12.24% -2.59% 5.66% -4.16% 10.73%
2011 10.32% 1.61% -20.78% 11.16% -1.30%
2010 8.25% -7.85% 16.61% 17.79% 37.01%
2009 -2.06% 24.50% 14.24% 5.91% 47.54%
2008 -21.75% 6.69% -11.69% -28.53% -47.31%
2007 4.75% 13.67% 9.96% 4.10% 36.29%
2006 16.07% -6.14% -6.74% 11.08% 12.86%
2005 -5.76% 5.86% 9.71% 2.62% 12.31%
2004 - - - 11.64% 6.39%

NAV Historical Prices

Date Net Asset Value

Portfolio

Portfolio

Portfolio Positioning as of 09/30/2019

  • The portfolio has moderated its overweight in the information technology sector relative to its benchmark, the Russell 2000® Growth Index.   Although we anticipate continued innovation in e-commerce and cloud computing companies, the outsized gains in these stocks over the past few years have led us to selectively reduce exposure.
  • Within the health care sector, we remain focused on innovative biotechnology companies, as large cap firms within the industry seek growth opportunities. Moreover, the portfolio maintains an overweight to health care equipment, specifically to innovative minimally-invasive medical device companies.
  • The portfolio remains underweight in certain bond proxy sectors, such as consumer staples and real estate, as we continue to believe these sectors are overvalued, considering they lack operating momentum and the fundamental characteristics that we favor. 
  • During the third quarter, the equity market continued to wrestle with trade war worries and interest rate volatility. Although the companies that we favor underperformed in this environment, we believe innovative growth companies continue to be very attractive over the long term. Furthermore, we believe that improving fundamentals and moderate inflation levels will continue to support higher equity prices for select innovative growth stocks.

Portfolio Details as of 10/31/2019

Total Net Assets
$1.80 B
Number of Holdings
92
Weighted Average Market Cap.
4.1 B
P/B Ratio
7.1x
P/E Ratio
33.6x

Contributors & Detractors as of  09/30/2019

Contributors

Holding Contribution
Acacia Communications, Inc. 0.3%
Appian Corp 0.3%
Inphi Corp. 0.3%
Insulet Corp. 0.3%
Nevro Corp. 0.3%

Detractors

Holding Contribution
Caredx Inc -0.7%
uniQure NV -0.6%
Everbridge, Inc. -0.5%
Blueprint Medicines Corp. -0.4%
Stitch Fix Inc -0.4%

Attribution Analysis 

Developing Growth Fund Benchmark Variance
Sector Avg. Weight Base Return Avg. Weight Base Return Stock Selection Group Weight Total

Dividends & Cap Gains

Dividends & Cap Gains

Upcoming Dividend Payment Dates

This section lists all anticipated Income and Capital Gain distribution dates and any actual distributions are subject to adequacy of earnings and must be approved by the Board of Directors/Trustees. Please note that dates are subject to change.

Record Date Ex-Dividend Date Reinvest & Payable Date
11/20/2019 11/21/2019 11/21/2019

Capital Gains Distributions

For
Record Date Reinvest & Payable Date Long-term Short-term * Total Reinvest Price
11/19/2018 11/20/2018 $6.2452 - $6.2452 $22.67

Upcoming Capital Gain Distribution

This section lists all anticipated Income and Capital Gain distribution dates and any actual distributions are subject to adequacy of earnings and must be approved by the Board of Directors/Trustees. Please note that dates are subject to change.

Record Date Ex-Dividend Date
11/20/2019 11/21/2019

Fees & Expenses

Fees & Expenses

Expense Ratioas of 10/31/2019

0.69%

Fund Documents

Fund Documents

Download fund documents & literature, create email subscriptions, and place direct mail order

0Documents selected
Order
Summary Prospectus
Publish Date:11/03/2015
n/a
Statutory Prospectus
Publish Date:11/03/2015
n/a
Prospectus (XBRL)
Publish Date:11/03/2015
SAI
Publish Date:11/03/2015
Annual Report
Publish Date:11/03/2015
Semi-Annual Report
Publish Date:11/03/2015
Fact Sheet
Publish Date:11/03/2015
Commentary
Publish Date:11/03/2015

To order literature visit full website

You may add to your cart by selecting quantities in each row below.

No rows selected. Please Go back and select at least one fund document

 
Quantity
Quantity
Remove
Remove

Class R5 - The inception date for Class R5 shares is June 30, 2015. The performance quotations for Class R5 are based on the following methods of calculation: (a) for periods prior to June 30, 2015, a restated figure is used based on the historical performance of the Fund’s portfolio since inception to reflect all charges and fees applicable to Class R5 shares; and (b) for periods after June 30, 2015, actual Class R5 performance is used, which reflects all charges and fees applicable to Class R5 shares.

Class R5 shares are only offered to certain eligible investors. For additional information, see the Fund’s current prospectus.

The Russell 2000® Growth Index measures the performance of those Russell 2000 companies with higher price-to-book ratios and higher forecasted growth values.

Select funds to run a Morningstar Hypothetical Report.

    Please confirm your literature shipping address

    Please review the address information below and make any necessary changes.

    All literature orders will be shipped to the address that you enter below. This information can be edited at any time.

    Current Literature Shipping Address

    * Required field